| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 |
| filingDate |
2009-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02f0068b228277c556a05dcbbe42d57f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93de87974c6f1be52728e609505f19da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d596592308329720bb403c5b4ca3c6c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1eba0abb3a4cecf3b9b7048492f542a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a54720073efd26e6542bcdf0e1ad21fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b7ed59bd0a5dc86c58c16b095a75648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0a47ef7a85f6838b34f6061dad6c157 |
| publicationDate |
2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-102099354-B |
| titleOfInvention |
Azole compound |
| abstract |
Disclosed is a compound useful as an active ingredient for a pharmaceutical composition for treating neurogenic pain. Extensive studies have been made on compounds having an inhibitory activity on FAAH. As a result, it is found that an azole compound substituted by an N-(pyridin-3- yl)oxycarbonyl-piperidin-4-yl group and a phenyl group or a pharmaceutically acceptable salt thereof has an excellent inhibitory activity on FAAH. The compound has an excellent inhibitory activity on FAAH, and it is confirmed that the compound has an antiallodynic effect in a rat neurogenic pain model. Therefore, the compound is useful as a prophylactic and/or therapeutic agent for neurogenic pain. |
| priorityDate |
2008-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |